Kick-starting the cancer-immunity cycle by targeting CD40
Författare
Summary, in English
Stimulation of CD40 on dendritic cells to expand and activate tumor-specific T cells and generate anticancer immunity is an attractive therapeutic approach. Since CD40 agonists exert their effects upstream of checkpoint inhibitors, including PD-1 or PD-L1 antagonists, they are ideal candidates for combination regimens.
Avdelning/ar
Publiceringsår
2015
Språk
Engelska
Sidor
1011484-1011484
Publikation/Tidskrift/Serie
OncoImmunology
Volym
4
Issue
7
Dokumenttyp
Artikel i tidskrift
Förlag
Landes Bioscience
Ämne
- Immunology in the medical area
Nyckelord
- CD40
- PD-1
- agonistic antibody
- immunooncology
Status
Published
ISBN/ISSN/Övrigt
- ISSN: 2162-4011